These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9471039)

  • 21. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
    Catalona WJ; Southwick PC; Slawin KM; Partin AW; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Loveland KG; Bray KR
    Urology; 2000 Aug; 56(2):255-60. PubMed ID: 10925089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.
    Brassell SA; Kao TC; Sun L; Moul JW
    Urology; 2005 Dec; 66(6):1229-33. PubMed ID: 16360448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate.
    Kalish J; Cooner WH; Graham SD
    Urology; 1994 May; 43(5):601-6. PubMed ID: 7513104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Volume adjustment for intermediate prostate-specific antigen values in a screening population.
    Bangma CH; Grobbee DE; Schröder FH
    Eur J Cancer; 1995; 31A(1):12-4. PubMed ID: 7535074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer.
    Ravery V; Chastang C; Toublanc M; Boccon-Gibod L; Delmas V; Boccon-Gibod L
    Eur Urol; 2000 Apr; 37(4):449-55. PubMed ID: 10765076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of prostate specific antigen (PSA) adjusted to transition zone in prostatic cancer detection].
    Jara Rascón J; Subirá Rios D; Lledó Garcia E; Martínez Salamanca JI; Moncada Iribarren I; Hernández Fernández C
    Actas Urol Esp; 2005 May; 29(5):485-92. PubMed ID: 16013794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy.
    Ravery V; Boccon-Gibod LA; Dauge-Geffroy MC; Billebaud T; Delmas V; Meulemans A; Toublanc M; Boccon-Gibod L
    Urology; 1994 Sep; 44(3):371-6. PubMed ID: 7521093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative prediction of extracapsular tumor extension at radical retropubic prostatectomy in Taiwanese patients with T1c prostate cancer.
    Ou YC; Chen JT; Yang CR; Cheng CL; Ho HC; Kao YL; Ko JL; Hsieh YS
    Jpn J Clin Oncol; 2002 May; 32(5):172-6. PubMed ID: 12110644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
    Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
    Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
    Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
    J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
    J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
    Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
    Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer?
    Giannarini G; Scott CA; Moro U; Pertoldi B; Beltrami CA; Selli C
    Urol Oncol; 2008; 26(4):353-60. PubMed ID: 18367100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate.
    Seaman EK; Whang IS; Cooner W; Olsson CA; Benson MC
    Urology; 1994 May; 43(5):645-8. PubMed ID: 7513107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
    Custovic Z; Kraus O; Tomaskovic I; Tarle M
    Anticancer Res; 2007; 27(4C):2817-21. PubMed ID: 17695453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
    Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
    J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer screening in the Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.